EyeCool Therapeutics, Inc.

Delivering fast, lasting relief for Chronic Ocular Surface Pain (COSP) patients. Investigational device not approved for marketing by the US FDA.

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Our new study in Ophthalmology and Therapy!

A 4-min treatment with our investigational device (ETX-4143) significantly reduced Chronic Ocular Surface Pain for up to 12 weeks with a favorable safety profile.

Read here: https://t.co/JF1J0SoiJL

#Ophthalmology #OcularPain

[EyeCool Therapeutics, Inc. @EyeCoolTx]

A new survey of 200+ eye care providers confirms patient symptoms drive Dry Eye treatment, not clinical signs.

At Eyecool Therapeutics, this validates our mission to address ocular surface pain directly.

Read the study: https://t.co/q36JvazIAH

#OcularSurfacePain

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Exciting News! A new Springer publication highlights EyeCool’s ETX-4143 device for Chronic Ocular Surface Pain. A single 4-minute treatment provided safe, long-lasting pain relief for a massive unmet need.

Read the open-access article: https://t.co/KJu1KvDfHC

#COSP #EyePain

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Exciting news!
EyeCool Therapeutics will present new 1-year data on ETX-4143 at #ARVO2026. Results show durable pain relief, zero adverse ocular effects, and improved corneal sensitivity for Chronic Ocular Surface Pain (COSP).

Read more: https://t.co/alBpS3vXh3

#MedTech #ECTX

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Chronic ocular surface pain (COSP) is often mistaken for dry eye, yet it is a distinct condition that disproportionately affects women.

EyeCool Therapeutics CEO Ruben F. Salinas, PhD, discusses why COSP is a major unmet need.

Read more: https://t.co/L4jxuzaWwl

#COSP #ECTX

[EyeCool Therapeutics, Inc. @EyeCoolTx]

EyeCool Therapeutics announced encouraging interim results from its ETX-4143 clinical study for chronic ocular surface pain, conducted at the University of Melbourne.

Read more: https://t.co/Y7Ybx3cEoG

#ChronicOcularSurfacePain #COSP #ClinicalStudy #UniversityOfMelbourne #ECTX

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Great to have Dr. Vance Thompson visit Cambridge and work with our engineering team. Ms. Angela Gu showcased the latest on our revolutionary technology and development progress.

#EyeCool #Innovation #MedicalDevices #Ophthalmology #Engineering

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Our Hot Seat video is live. COSP affects many patients and current treatments fall short. We’re building a solution designed for faster, more meaningful relief.

If our mission resonates, please vote for us.

🎥 Watch: https://t.co/uEgYd2Oz7j
🗳️ Vote: https://t.co/q3chZv0ldc

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Great discussions and positive feedback at #InnovatorsPopUp 2025 in Orlando.

Exciting to connect with so many innovators shaping the future of eye care.

#Ophthalmology #Innovation #EyeCare #AAO

[EyeCool Therapeutics, Inc. @EyeCoolTx]

New insights from Healio show low provider satisfaction with current COSP treatments, highlighting a clear call for more effective, targeted care options.

🔗 Read more: https://t.co/bIapQ7bCes

#Ophthalmology #COSP #Innovation

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Only one week until #InnovatorsPopUp at #AAO!

Dr. Cristos Ifantides will be in the Hot Seat sharing how our non-invasive tech is advancing care for patients with chronic ocular surface pain (COSP).

📍 Orlando | Oct 16 | https://t.co/QSgrBtxAcX

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Exciting news! A new publication, “The Safety and Tolerability of a Single Scleral Treatment With a Cooling Device in Rabbits,” features results from a preclinical study using our cooling device technology.

Link: https://t.co/HO5gnH2vcV

#Ophthalmology #COSP #MedicalDevice #ECTX

[EyeCool Therapeutics, Inc. @EyeCoolTx]

✨🔥 Mark your calendars! Our Chief Medical Advisor, Cristos Ifantides MD, MBA, is taking on the Hot Seat at Innovators Pop-Up on October 16, 2025.

Reserve your spot today at https://t.co/QSgrBty82v.

#InnovatorsPopUp #Ophthalmology #Innovation #AAO

[EyeCool Therapeutics, Inc. @EyeCoolTx]

We’re thrilled to welcome Dr. Vance Thompson to EyeCool Therapeutics’ Board of Directors, and to announce our new Medical Advisory Board of world-renowned ophthalmologists guiding innovation in ocular therapeutics.

🔗 https://t.co/EpfsPLC1jr
#Ophthalmology #EyeCoolTx

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Our team is wrapping up work on our last GLP study, and everything went according to plan ✅. We’re incredibly proud of our product development and clinical support teams for their precision, dedication, and teamwork driving EyeCool’s mission forward.

#Innovation #Teamwork #ETX

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Excited to share that our Scientific Advisory Board Chair, Dr. Anat Galor, will present her abstract, “Prevalence and Management of Chronic Ocular Surface Pain (COSP) in US Eyecare Clinics,” as an On-Demand Poster at @aao_ophth 2025 in Orlando.

#AAO2025 #COSP #EyeCoolTx

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Earlier this month, we supported the Dry Eye in DC Reception—an evening of dialogue and shared commitment.

EyeCool is proud to stand with this community and remains focused on relief for those living with COSP.

#EyeCoolTherapeutics #COSP #DryEye #PatientAdvocacy #Ophthalmology

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Last May, on EyeCool’s anniversary, our CEO Dr. Ruben F. Salinas reached the summit of Mt. Everest.
At 29,032 feet, he showed the same focus and grit that fuel our mission.
From the top of the world, we keep climbing.
📸Summit day
#EyeCoolTherapeutics #Leadership #Everest #ToTop

[EyeCool Therapeutics, Inc. @EyeCoolTx]

EyeCool Therapeutics, Inc. announced positive data from a randomized controlled pilot study (n=31) in Australia evaluating its investigational device ETX-4143 for the treatment of Chronic Ocular Surface Pain (COSP).
🔗 https://t.co/t3RUR6uRZD
#EyeCoolTherapeutics #COSP #MedTech

[EyeCool Therapeutics, Inc. @EyeCoolTx]

Had a great time at the ASCRS Annual Meeting connecting with leading ophthalmology clinicians and sharing our technology.
Thanks to everyone who stopped by to learn more. Exciting things ahead!
#COSP #ASCRS #Ophthalmology #MedTech #EyeCare #EyeCoolTherapeutics